文献速递甲状腺疾病

甲状腺乳头状癌中程序性死亡配体1的表达及其与临床病理因素和复发的关系

Programmed Death-Ligand 1 Expression in Papillary Thyroid Cancer and Its Correlation with Clinicopathologic Factors and Recurrence.
PubMed 文献 · Thyroid · 2017-01-24

该研究回顾性采用免疫组化检测260例甲状腺乳头状癌(PTC)肿瘤及对应非肿瘤组织中程序性死亡配体1(PD-L1)的表达,分析其与临床病理特征及无复发生存(RFS)的相关性。结果显示52.3%(136/260)的PTC肿瘤组织PD-L1表达阳性,显著高于对应非肿瘤甲状腺组织;作者认为PD-L1在决定PTC侵袭性中起重要作用并可预测患者预后,建议将抑制PD-L1作为治疗高表达PD-L1的晚期PTC的潜在策略。

要点

  • PTC肿瘤组织PD-L1阳性率为52.3%(136/260),显著高于对应非肿瘤甲状腺组织。
  • PD-L1阳性与多灶性(p=0.001)和甲状腺外侵犯(p=0.001)正相关。

核心结论

  • PD-L1在决定PTC侵袭性中起重要作用,并可预测患者预后。
  • 作者建议将抑制PD-L1作为治疗高表达PD-L1的晚期PTC的潜在策略。

研究设计与样本

  • 回顾性研究,采用免疫组化染色评估260例PTC肿瘤及对应非肿瘤组织中PD-L1的表达。
  • 分析PD-L1表达与临床病理特征及无复发生存(RFS)的相关性。

主要发现

  • PD-L1在52.3%(136/260)的PTC肿瘤组织中表达阳性,显著高于对应非肿瘤甲状腺组织。
  • PD-L1阳性染色与多灶性(p=0.001)和甲状腺外侵犯(p=0.001)正相关。
  • 亚组分析中,肿瘤组织PD-L1阳性染色与更差RFS相关:男性(p=0.001)、年龄≥45岁(p=0.001)、原发肿瘤大小>4 cm(p=0.002)、多灶性肿瘤(p=0.031)、甲状腺外侵犯(p=0.012)、淋巴结转移(p=0.004)。
  • 亚组分析中,PD-L1阳性染色预测更差RFS见于无桥本甲状腺炎亚组(p=0.001)和接受甲状腺全切术亚组(p=0.019)。

临床怎么用

  • 作者认为PD-L1在决定PTC侵袭性中起重要作用并可预测预后。
  • 作者建议将抑制PD-L1作为治疗高表达PD-L1的晚期PTC的潜在策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Programmed death-ligand 1 (PD-L1) expression has been reported in several malignancies, but the expression of PD-L1 in papillary thyroid cancer (PTC) has been characterized rarely. The aim of this study was to assess the significance of PD-L1 expression and its associations with clinicopathologic factors and disease outcome in PTC. METHODS: Immunohistochemistry staining was conducted retrospectively to evaluate the expression of PD-L1 in a total of 260 PTC tumors and corresponding non-tumor tissues. The correlations between PD-L1 expressions with clinicopathologic features and recurrence-free survival (RFS) were analyzed. RESULTS: PD-L1 expression was positive in 52.3% (136/260) of PTC tumor tissues, which was significantly higher than in corresponding non-tumor thyroid tissues. In clinicopathologic analyses, this positive staining of PD-L1 was positively linked to multifocality (p = 0.001) and extrathyroidal extension (p = 0.001). In multivariate Cox regression analysis, positive PD-L1 expression in tumor tissue was significantly associated with worse RFS (hazard ratio 2.825 [confidence interval 1.149-6.943], p = 0.024). In subgroup analyses based on clinicopathologic factors, positive PD-L1 staining of tumor tissue was associated with worse RFS in males (p = 0.001), older patients (≥45 years; p = 0.001), and patients with a primary tumor size >4 cm (p = 0.002), multifocal tumors (p = 0.031), extrathyroidal extension (p = 0.012), and lymph node metastasis (p = 0.004). In contrast, positive PD-L1 staining predicted worse RFS in the subgroup of patients without Hashimoto's thyroiditis (p = 0.001) and treated with total thyroidectomy (p = 0.019). CONCLUSIONS: PD-L1 is important in determining aggressiveness of PTC and could predict the prognosis of patients. Therefore, inhibition of PD-L1 is suggested as a potential strategy for the treatment of advanced PTC with high expression of PD-L1.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Shi RL, Qu N, Luo TX, et al. Programmed Death-Ligand 1 Expression in Papillary Thyroid Cancer and Its Correlation with Clinicopathologic Factors and Recurrence. Thyroid. 2017. PMID: 27825291. doi:10.1089/thy.2016.0228

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。